In the Phase 2 COURAGE trial, semaglutide 2.4 mg alone lost approximately 7 kg fat and 3 kg lean mass over 26 weeks, with roughly 35% of total weight loss from lean tissue. Adding trevogrumab (anti-GDF8/myostatin) cut lean-mass loss by approximately half while amplifying fat-mass reduction, without attenuating total weight loss or metabolic benefits.
What Is Trevogrumab and How Does It Interact With GLP-1 Pharmacology?
Trevogrumab (REGN1033) is a human monoclonal antibody that neutralizes GDF8 (myostatin), a TGF-beta superfamily ligand that suppresses skeletal muscle protein synthesis via ActRIIB-ALK4/5-SMAD2/3 signaling. GLP-1 receptor agonists like semaglutide drive caloric deficits that upregulate myostatin activity, accelerating muscle catabolism. Trevogrumab interrupts this catabolic amplification at the ligand level.
Myostatin binds ActRIIB, recruits ALK4/5 as a co-receptor, and phosphorylates SMAD2/3, which translocates to the nucleus to suppress myofibrillar gene expression. This cascade simultaneously upregulates atrophy-associated ubiquitin ligases including Atrogin-1. During energy deficit, circulating myostatin rises in proportion to the caloric shortfall, making GLP-1-driven weight loss a particularly high-myostatin-activity state.
Trevogrumab is GDF8-selective and does not cross-react with GDF11 or activin A at therapeutic concentrations, as confirmed by Mastaitis et al (2025, PMC12075787). This selectivity matters for interpreting COURAGE's dose-response data. Activin A blockade via garetosmab adds a mechanistically distinct, more-than-additive layer on top of GDF8 neutralization.
What Did the COURAGE Phase 2 Trial Actually Measure?
COURAGE was a Phase 2 randomized trial in adults with obesity testing semaglutide 2.4 mg weekly alone versus semaglutide combined with trevogrumab (200 mg or 400 mg) with or without garetosmab over 26 weeks. Primary endpoints included DXA-measured lean mass and fat mass. A predefined MRI substudy quantified thigh muscle volume as a direct structural endpoint.
The trial's design separated body-composition quality from total weight loss, distinguishing COURAGE from standard obesity pharmacology trials. All semaglutide-containing arms achieved comparable total weight loss of approximately 10%. This established that lean-mass differences were not confounded by differential energy deficit magnitude.
A lower-dose extension enrolled participants on trevogrumab 25 mg or 75 mg combined with semaglutide 2.4 mg for 52 weeks. Regeneron presented complete 26-week results at EASD 2025 and full 52-week lower-dose data in 2026. MRI substudy findings were reported in the same conference cycle.
What Are the Actual Lean-Mass and Fat-Mass Numbers?
Semaglutide monotherapy produced approximately 7 kg fat loss and 3 kg lean-mass loss at 26 weeks, with lean tissue comprising roughly 35% of total loss. Trevogrumab 400 mg compressed lean-mass loss to approximately half that rate while pushing fat reduction from about 16% to about 19%. The MRI substudy found trevogrumab prevented approximately 70% of thigh muscle-volume loss.
The fat-mass amplification is as numerically significant as the lean-mass protection. Semaglutide alone reduced fat mass by about 16%, while the 400 mg trevogrumab arm reached about 19%, a 3-plus percentage-point absolute gain in fat-specific reduction. This pattern suggests myostatin blockade redirects the caloric deficit toward adipose mobilization rather than simply preserving muscle at the expense of fat loss.
The triple combination arm (semaglutide plus trevogrumab plus garetosmab) produced the most extreme body-composition shift. Aimelet et al (PMC12803604, 2025) reported that co-administration nearly doubled fat-mass reduction relative to semaglutide monotherapy. The triple arm lost nearly 12 kg fat mass and under 1 kg lean mass, a lean fraction below 8% of total weight lost.
Are Semaglutide's Metabolic Benefits Preserved or Attenuated When Trevogrumab Is Added?
Metabolic parameters were not attenuated. COURAGE's complete 26-week data showed numerical improvements in waist circumference, high-sensitivity CRP, and lipid parameters in the trevogrumab arms versus semaglutide monotherapy. No statistically significant worsening of glycemic markers, insulin sensitivity, or cardiovascular risk parameters was observed with trevogrumab addition at either dose tested.
Myostatin blockade increases skeletal muscle mass, and greater muscle mass independently improves insulin-mediated glucose disposal via GLUT4 upregulation. The combination therefore creates a dual metabolic benefit: semaglutide's direct GLP-1R-mediated insulin sensitization is augmented by the indirect insulin-sensitizing effect of a larger muscle compartment. This mechanistic layering is the key performance-relevant finding.
Waist circumference reductions trended larger in the combination arms, consistent with the DXA finding that fat-mass loss was amplified. Whether these numerical improvements reach statistical significance in a Phase 3 trial with adequate power for metabolic endpoints remains open. COURAGE was not powered for cardiovascular or glycemic outcomes.
What Does Garetosmab Add, and Is the Triple Combination More-Than-Additive?
Garetosmab is an anti-activin A monoclonal antibody. Activin A signals through ActRIIB but is not blocked by trevogrumab. COURAGE data showed the triple combination produced more-than-additive improvements in both muscle preservation and fat reduction, consistent with dual-ligand blockade of the ActRIIB axis creating a broader anabolic shift than either antibody alone achieves.
Aimelet et al (2025) characterized this as a dose-dependent, more-than-additive pattern, suggesting GDF8 and activin A exert partially independent suppressive effects on muscle mass. Blocking both simultaneously removes a larger fraction of total ActRIIB-mediated catabolic tone. Mastaitis et al (2025) demonstrated this pattern in obese mice and non-human primates before COURAGE confirmed it in humans.
The triple combination arm showed a substantially higher rate of discontinuations due to tolerability compared with the dual combination. This tolerability signal is the primary constraint on the triple-combination approach. It will determine whether garetosmab advances to Phase 3 alongside trevogrumab or as a separate development program.
What Is the Safety Profile of Trevogrumab in the COURAGE Context?
The semaglutide plus trevogrumab dual combination was generally well-tolerated in COURAGE. Adverse events occurring in 5% or more of any treatment group included muscle spasms, nausea, constipation, fatigue, and diarrhea. Muscle spasm incidence was dose-dependent, rising from under 5% with semaglutide alone to over 9% with trevogrumab 400 mg.
Nausea, constipation, and diarrhea are established semaglutide-class effects and did not increase meaningfully with trevogrumab addition. This indicates the GI tolerability profile is driven by GLP-1R agonism rather than myostatin blockade. No new safety signals attributable specifically to trevogrumab were identified in the 26-week dataset.
Trevogrumab remains investigational with no regulatory approval as of 2026. All COURAGE data are Phase 2. Extrapolating the safety profile to longer durations, different populations, or co-administration with agents other than semaglutide is not supported by current evidence.
What Are the Body-Composition Implications for GLP-1 Users?
At semaglutide's 35% lean fraction, a 15 kg weight-loss course costs approximately 5 kg of lean tissue. Trevogrumab's roughly 50% lean-mass attenuation reduces that to approximately 2 to 3 kg, a meaningful absolute preservation without altering the fat-loss trajectory. This exceeds what most behavioral interventions achieve pharmacologically in the same context.
The fat-mass amplification effect is equally relevant for body-composition practitioners. A 15 kg total weight-loss course on semaglutide monotherapy loses approximately 10 kg of fat. Trevogrumab 400 mg's approximately 19% fat-mass reduction versus 16% represents a 22% relative increase in fat-specific loss, shifting the fat-to-lean loss ratio from roughly 2:1 toward 5:1 or better.
The MRI substudy's 70% thigh muscle-volume preservation finding is the most structurally specific number in COURAGE. Thigh muscle volume correlates with strength, metabolic rate, and long-term weight-maintenance outcomes. Preserving 70% of what would otherwise be lost represents a mechanistically meaningful structural outcome.
What Are the Evidence-Quality Constraints on These Findings?
COURAGE is a single Phase 2 trial, industry-sponsored by Regeneron, with a 26-week primary endpoint in a BMI 30 or above population. It was not powered for metabolic, cardiovascular, or functional outcomes. No independent replication exists as of 2026, and the combination has no long-term safety data beyond 52 weeks in the lower-dose extension cohort.
The trial did not control for dietary protein intake, resistance training, or baseline muscle mass, all of which independently modulate lean-mass outcomes during GLP-1 therapy. The lean-mass preservation effect of trevogrumab may therefore be additive to, or partially redundant with, structured resistance training in practice. COURAGE was not designed to answer that interaction question.
Phase 3 trials will need to establish whether body-composition advantages translate to functional endpoints such as strength, physical performance, and weight-regain prevention. The 52-week lower-dose data and MRI substudy provide directional support. The evidence base remains Phase 2 and industry-generated as of 2026. Which GLP-1/GIP Combination Peptide Protocols Best Preserve Lean Mass While Improving Glycemic Control in 2026 Self-Experimentation? Does Retatrutide's Phase 3 Evidence in 2026 Show Clinically Meaningful Weight Loss Beyond Semaglutide and Tirzepatide? What Do 2026 Primary Studies Show About GLP-1/GIP Dual Agonists Versus GLP-1 Monotherapy for Body-Weight Loss and Cardiometabolic Outcomes?